GSG Advisors’s Boston Scientific BSX Stock Holding History

GSG Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,487	Closed	-$334K	–	137
2025 Q3	$334K	Hold	3,487	–	–	0.09%	91
2025 Q2	$375K	Sell	3,487 -1,595	-31%	-$161K	0.11%	82
2025 Q1	$492K	Buy	5,082 +174	+4%	+$17.5K	0.16%	67
2024 Q4	$438K	Buy	4,908 +20	+0.4%	+$1.76K	0.14%	71
2024 Q3	$411K	Buy	4,888 +200	+4%	+$15.8K	0.14%	74
2024 Q2	$358K	Buy	+4,688	New	+$343K	0.13%	75

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

GSG Advisors's BSX Position: Q4 2025 in Review

GSG Advisors sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 3,487 shares — an estimated $334K sold.

GSG Advisors first reported a position in BSX in Q2 2024 and held it in 6 quarters. The position peaked at $492K in Q1 2025. 1,791 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

GSG Advisors reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
GSG Advisors sold 3,487 Boston Scientific shares in Q4 2025, an estimated $334K.
GSG Advisors first reported a position in Boston Scientific in Q2 2024 and held it in 6 quarters.
GSG Advisors's Boston Scientific position peaked at $492K in Q1 2025.
1,791 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on GSG Advisors's 13F filing for Q4 2025, filed 8 Jan 2026.